A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
This study is exploring whether a new medicine, spesolimab, can help adults with a skin condition called pyoderma gangrenosum (PG). The main goal is to see if spesolimab leads to the healing of PG ulcers. Participants will receive either spesolimab or a placebo (a dummy medicine) through a drip, along with steroid tablets initially. The study runs in two parts, with treatment assigned by chance. Doctors will regularly check participants' skin, health, and any side effects over about 1.5 years. The results will help determine if spesolimab is an effective treatment for PG.
A colpo d'occhio
Di cosa tratta questo studio?
You might be reading this because you or someone you know has pyoderma gangrenosum (PG), a difficult skin condition. This study is looking into a new medicine called spesolimab. The main idea is to find out if spesolimab can help heal the ulcers (open sores) that are a common problem with PG. If it works, it could offer a new way to treat this condition.
The study involves adults who have ulcerative PG, meaning they have ulcers on their skin. The ulcers need to be a certain size to join the study. Researchers want to compare spesolimab with a placebo, which looks like the real medicine but doesn't contain any active ingredients. This helps them truly understand if the medicine itself is making a difference.
By taking part, you would be helping doctors and scientists learn more about PG and how to treat it. Every participant's experience provides valuable information, bringing us closer to better treatments for everyone with this condition.
Punti chiave
- This study tests if spesolimab helps heal pyoderma gangrenosum (PG) ulcers.
- It involves adults with specific types of PG ulcers.
- You might receive spesolimab or a placebo, plus steroid tablets initially.
- Treatment is given as a drip every four weeks.
- The study lasts about 1.5 years with regular clinic visits.
- Your participation helps to advance PG treatment research.
Chi può essere idoneo?
To be able to join this study, you need to be an adult, aged 18 or over. You must also have a clear diagnosis of ulcerative pyoderma gangrenosum (PG), which means you have ulcers on your skin related to this condition. These ulcers need to be a certain size, not too small and not too large (between 5 and 80 square centimetres).
Your PG ulcer should also have been diagnosed within the last six months, though some older, active ulcers might be considered. It's important that your ulcers are not infected when you start the study. Also, if you are a woman who could become pregnant, you'll need to agree to use effective birth control throughout the study.
You cannot join if you have other types of skin sores that are not PG, or if your PG ulcers are very large. Also, if your ulcers are chronic and don't respond to usual treatments that calm the immune system, you might not be suitable for this particular study.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Have you been diagnosed with ulcerative pyoderma gangrenosum (PG)?
- Do you have at least one PG ulcer between 5 and 80 square centimetres in size?
- Is your PG ulcer not currently infected?
- If you are a woman, are you willing to use effective birth control during the study?
- Do you not have other types of skin sores that are not PG?
Cosa comporta la partecipazione?
If you decide to join this study, it will last for about 1.5 years. During this time, you'll visit the study clinic 20 times. At these visits, doctors will carefully check your skin – especially your PG ulcers – to see how they are healing. They will also keep a close eye on your general health and write down any side effects you might experience.
In the study, you'll receive either the medicine spesolimab or a placebo (a dummy medicine) through a drip into your arm. This drip will be given every four weeks. For the first eight weeks, all participants will also take steroid tablets by mouth. The study involves two parts, and the treatment you receive will be decided by chance, meaning it's random.
If you have open ulcers, during the second part of the study, you will receive spesolimab. If your ulcers have healed, you might get either spesolimab or the placebo. You can also withdraw from the study at any time.
Rischi e benefici potenziali
Locations (96)
- Università dell'Alabama a BirminghamCodice postale verificatoBirmingham, Stati Uniti· Reclutamento
- Medical Dermatology Specialists PhoenixCodice postale verificatoPhoenix, Stati Uniti· Reclutamento
- University of California IrvineCodice postale verificatoIrvine, Stati Uniti· Reclutamento
- University of MiamiCodice postale verificatoMiami, Stati Uniti· Reclutamento
- University of South FloridaCodice postale verificatoTampa, Stati Uniti· Reclutamento
- Ada West ResearchCodice postale verificatoMeridian, United States· Non ancora in fase di reclutamento
- Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995Codice postale verificatoIndianapolis, Stati Uniti· Reclutamento
- Brigham and Women's HospitalCodice postale verificatoBoston, Stati Uniti· Reclutamento
- Università del MichiganCodice postale verificatoAnn Arbor, Stati Uniti· Reclutamento
- Dartmouth Hitchcock Clinics Heater RoadCodice postale verificatoLebanon, United States· Reclutamento
- Dermatology at Lake SuccessCodice postale verificatoLake Success, Stati Uniti· Reclutamento
- Icahn School of Medicine at Mount SinaiCodice postale verificatoNew York, Stati Uniti· Reclutamento
Domande comuni
What is pyoderma gangrenosum (PG)?
Pyoderma gangrenosum is a rare skin condition that causes painful sores or ulcers, especially on the legs. It's not an infection but is thought to be an autoimmune problem.
Che cos'è un placebo?
A placebo is a substance that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the actual drug against no treatment.
Why do some people get a placebo?
Giving some participants a placebo helps doctors understand if the new medicine is truly working or if improvements are due to other factors. This makes the study results more reliable.
Per quanto tempo sarò nello studio?
You will be in this study for approximately 1.5 years (about 18 months).
Posso smettere di partecipare allo studio in qualsiasi momento?
Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.
Come saperne di più
Boehringer Ingelheim
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.